PubRank

Thomas P Loughran

Author PubWeight™ 90.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012 4.15
2 Microarray results: how accurate are they? BMC Bioinformatics 2002 3.23
3 Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2008 2.60
4 STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012 2.55
5 How I treat LGL leukemia. Blood 2010 2.38
6 T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma 2011 2.37
7 Large granular lymphocyte leukemia. Oncologist 2006 2.21
8 Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013 1.80
9 The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol 2010 1.67
10 Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 2011 1.63
11 Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012 1.61
12 STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 2013 1.59
13 ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 2004 1.56
14 Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012 1.53
15 Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol 2011 1.51
16 Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003 1.50
17 Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program 2012 1.45
18 Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008 1.45
19 Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy 2011 1.44
20 Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002 1.38
21 Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 2005 1.34
22 Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 2007 1.32
23 NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest 2011 1.30
24 Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 2011 1.22
25 Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 2011 1.20
26 Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev 2006 1.19
27 Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2009 1.17
28 Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010 1.14
29 Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010 1.12
30 Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program 2004 1.10
31 Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010 1.09
32 Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004 1.09
33 A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 2008 1.07
34 Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002 1.05
35 Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol 2003 1.04
36 Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011 1.03
37 Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 2009 1.02
38 Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. Int J Oncol 2005 1.02
39 The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol 2011 1.01
40 Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res 2007 0.98
41 HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy. J Biol Chem 2012 0.98
42 Survival signals in leukemic large granular lymphocytes. Semin Hematol 2003 0.97
43 Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008 0.96
44 Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol 2012 0.93
45 Large granular lymphocyte leukemia. Curr Hematol Malig Rep 2007 0.92
46 Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta 2002 0.92
47 Liver injury during acute pancreatitis: the role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis. J Gastrointest Surg 2003 0.88
48 The effect of selenium enrichment on baker's yeast proteome. J Proteomics 2011 0.88
49 Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med 2014 0.87
50 Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res 2004 0.86
51 Galaxy tools to study genome diversity. Gigascience 2013 0.84
52 A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment. Toxicol Sci 2007 0.83
53 Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cell Immunol 2002 0.81
54 Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. Leuk Lymphoma 2012 0.81
55 Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma 2009 0.81
56 Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs 2010 0.81
57 Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor. Int J Hematol 2002 0.80
58 Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res 2012 0.80
59 Multiple myeloma presenting as CEA-producing rectal cancer. Rare Tumors 2010 0.80
60 Perspectives in the treatment of LGL leukemia. Leuk Res 2005 0.78
61 Responses to a theoretically adapted clinical trial education session: faith-based sites versus rural work site dissemination. J Cancer Educ 2013 0.78
62 Antigen-driven clonal T cell expansion in disorders of hematopoiesis. Leuk Res 2003 0.78
63 Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. Br J Haematol 2014 0.78
64 Targeting IL-15 in large granular lymphocyte leukemia. Expert Rev Clin Immunol 2013 0.77
65 Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)]. Anticancer Agents Med Chem 2011 0.77
66 Estimation of daily proteinuria in patients with multiple myeloma by using the protein-to-creatinine ratio in random urine samples. Acta Haematol 2010 0.77
67 Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. Curr Treat Options Oncol 2003 0.77
68 Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J Acquir Immune Defic Syndr 2003 0.77
69 Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol 2013 0.77
70 Targeting sphingosine-1-phosphate receptors in cancer. Anticancer Agents Med Chem 2011 0.76
71 Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother 2011 0.75
72 Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Cancer Biol Ther 2014 0.75
73 Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast? Leuk Lymphoma 2011 0.75
74 Putting HIV-1 apoptosis mediators to work against cancer: a killer job, with benefits. Cancer Biol Ther 2009 0.75
75 Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes. Leuk Lymphoma 2011 0.75
76 Diagnosing large granular lymphocyte leukemia is bloody difficult. Leuk Lymphoma 2012 0.75
77 Developing an in vitro model of T cell type of large granular lymphocyte leukemia. Leuk Res 2013 0.75
78 Does IL-15 have a causative role in large granular lymphocyte leukemia? Immunotherapy 2013 0.75
79 Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature. Blood Coagul Fibrinolysis 2015 0.75
80 Immunotherapy of hematologic malignancies: the road to the future. Cancer Control 2002 0.75
81 Development and use of ceramide nanoliposomes in cancer. Methods Enzymol 2012 0.75
82 Characterization of a variant of PAC-1 in large granular lymphocyte leukemia. Protein Expr Purif 2003 0.75
83 New clues to accrue on neutropenia in rheumatoid arthritis. Clin Immunol 2005 0.75
84 Impact of genetic targets on cancer therapy in acute myelogenous leukemia. Adv Exp Med Biol 2013 0.75
85 Imaging of glenoid labrum lesions. Clin Sports Med 2013 0.75
86 Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. Eur J Haematol 2014 0.75
87 Retroperitoneal diffuse large B-cell lymphoma presenting as pseudoachalasia. J Clin Oncol 2010 0.75
88 Problems associated with product enhancement reverse transcriptase assay using bacteriophage MS2 RNA as a template. J Virol Methods 2003 0.75